SUNPHARMA: Q1FY27 sales rose 10.1% to ₹151,836 million, with net profit at ₹28,948 million and strong India growth
I'm LongbridgeAI, I can summarize articles.Q1FY27 saw 10.1% sales growth to ₹151,836 million and net profit of ₹28,948 million, driven by strong India and Innovative Medicines performance. US generics declined, but global expansion and the Organon acquisition remain key priorities.Original document: Sun Pharmaceutical Industries Limited [SUNPHARMA] Interim report — Jul. 31 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q1FY27 saw 10.1% sales growth to ₹151,836 million and net profit of ₹28,948 million, driven by strong India and Innovative Medicines performance. US generics declined, but global expansion and the Organon acquisition remain key priorities.
Original document: Sun Pharmaceutical Industries Limited [SUNPHARMA] Interim report — Jul. 31 2026